Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography

Hypertension

Volumn 33, Issue 4, 1999, Pages 961-968

  Yoshiyama, Minoru ^a   Takeuchi, Kazuhide ^a   Omura, Takashi ^a   Kim, Shokei ^a   Yamagishi, Hiroyuki ^a   Toda, Iku ^a   Teragaki, Masakazu ^a   Akioka, Kaname ^a   Iwao, Hiroshi ^a   Yoshikawa, Junichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diastole; Echocardiography; Genes; Myocardial infarction; Receptors, angiotensin; Ventricular remodeling

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CANDESARTAN; CILAZAPRIL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYOSIN HEAVY CHAIN;

ANIMAL MODEL; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA ANALYSIS; SYSTOLE;

EID: 0032941861     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.4.961     Document Type: Article

References (39)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-1435.
2. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators [see comments]. N Engl J Med. 1991;325:293-302.
3. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown E Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators [see comments]. N Engl J Med. 1992;327:669-677.
4. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group [see comments]. Lancet. 1995;345:669-685.
5. Inada Y, Terashita Z, Imura Y, Tanabe M, Nishikawa K, Kikuchi S. Inhibition of angiotensin converting enzyme by CV-3317, a nonsulfhydryl compound. Jpn J Pharmacol. 1986;42:99-108.
6. Wood JM, Mah SC, Schnell C. Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats. J Cardiovasc Pharmacol. 1990;16:S60-S64.
7. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PB, Morkin E. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 1991;4:334S-340S.
8. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99: 1926-1935.
9. McDonald KM, Garr M. Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, Cohn JN. Relative effects of α 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90:3034-3046.
10. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol. 1996;27:714-719.
11. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
12. Spinale FG, Holzgrefe HH, Mukherjee R, Webb ML, Hird RB, Cavallo MJ, Powell JR, Koster WH. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes. J Pharmacol Exp Ther. 1997;283:1082-1094.
13. Wollen KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation. 1997;95:1910-1917.
14. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol. 1993;25:1369-1380.
15. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
16. Yusuf S, Maggioni A, Held P, Rouleau. Effects of Candesartan, Enalapril or Their Combination on Exercise Capacity, Ventricular Function, Clinical Deterioration and Quality of Life in Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD). Circulation. 1997;96:I-452. Abstract.
17. Thomas JD, Weyman AE. Echocardiographic Doppler evaluation of left ventricular diastolic function: physics and physiology. Circulation. 1991; 84:977-990.
18. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354.
19. Pawlush DG, Moore RL, Musch TI, Davidson W Jr. Echocardiographic evaluation of size, function, and mass of normal and hypertrophied rat ventricles. J Appl Physiol. 1993;74:2598-2605.
20. Fishbein MC, Maclean D, Maroko PR. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol. 1978;90:57-70.
21. Gay RG. Early and late effects of captopril treatment after large myocardial infarction in rats. J Am Coll Cardiol. 1990;16:967-977.
22. Scherrer-Crosbie M, Steudel W, Hunziker PR, Foster GP, Garrido L, Liel-Cohen N, Zapol WM, Picard MH. Determination of right ventricular structure and function in normoxic and hypoxic mice. Circulation. 1998; 98:1015-1021.
23. Yoshiyama M, Takeuchi K, Hanatani A, Shimada T, Takemoto Y, Shimizu N, Omura T, Kim S, Iwao H, Yoshikawa J. The effect of cilazapril on ventricular remodeling assessed by Doppler echocardiographic assessment and cardiac gene expression. Cardiovasc Drug Ther. 1998;12:57-70.
24. + exchanger genes between adjacent and remote noninfarcted myocardium after myocardial infarction. J Mol Cell Cardiol. 1997;29:255-264.
25. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
26. Pouleur H, Rousseau MF, van-Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict CR, Yusuf S, Konstam M. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction: SOLVD Investigators. Circulation. 1993;88:481-491.
27. Hanatani A, Yoshiyama M, Takeuchi K, Kim S, Nakayama K, Omura T, Iwao H, Takeda T. Angiotensin II type 1 receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats. Jpn J Pharmacol. 1998;78:45-54.
28. Litwin SE, Katz SE, Morgan JP, Douglas PS. Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction. J Am Coll Cardiol. 1996;28:773-781.
29. Litwin SE, Litwin CM, Raya TE, Warner AL, Goldman S. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition. Circulation. 1991;83:1028-1037.
30. Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling and β-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res. 1992;71:797-807.
31. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74:693-702.
32. Eleftheriades EG, Durand JB, Ferguson AG, Engelmann GL, Jones SB, Samarel AM. Regulation of procollagen metabolism in the pressure-overloaded rat heart. J Clin Invest. 1993;91:1113-1122.
33. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91: 2043-2048.
34. Whitebread S, Mele M, Kamber B, de-Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284-291.
35. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92: 10663-10667.
36. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
37. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
38. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
39. Nunez E, Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 1997;29:519-524.